Gilead’s (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
ZacksGilead Sciences, Inc.’s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Gilead Sciences, Inc.’s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.